33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis - Update of clinical and translational data from the ongoing MANIFEST trial
    Meeting Abstract

    Kremyanskaya, M.; Mascarenhas, J.; Palandri, F.; Vannucchi, A.; Verstovsek, S.; Harrison, C. N.; Bose, P.; Schiller, G. J.; Rampal, R.; Drummond, M. W.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Comparative analysis of mature T-cell and NK/T-cell lymphomas in patients with and without HIV: Results from the NA-ACCORD and complete cohorts
    Meeting Abstract

    Koh, M. J.; Merrill, M. H.; Koh, M. J.; Stuver, R. N.; Alonso, C. D.; Foss, F. M.; Mayor, A. M.; Gill, M. J.; Epeldegui, M.; Cachay, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Chromatin accessibility profiling to increase diagnostic accuracy and refine cell-of-origin classification of mature T-cell lymphomas
    Meeting Abstract

    Julia, E.; Mareschal, S.; Chebel, A.; Golfier, C.; Mùˆller, T. A.; Lours, C.; Hadj-Hamou, S.; Bissay, N.; Tschanz, M.; Ceribelli, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The High Mobility Group A1 chromatin regulator drives immune evasion during MPN progression by repressing genes involved in antigen presentation and immune attack
    Meeting Abstract

    Kim, J.; Kim, J. H.; Cope, L.; Li, L.; Rampal, R.; Koche, R.; Williams, D. M.; Spivak, J. L.; Moliterno, A. R.; Resar, L.
    Blood (2021)

    Fulltext@MSK | Save
  • Subcutaneous epcoritamab in patients with relapsed/refractory chronic lymphocytic leukemia: Preliminary results from the EPCORE CLL-1 trial
    Meeting Abstract

    Kater, A. P.; Christensen, J. H.; Bentzen, H. H.; Niemann, C. U.; Hutchings, M.; Chen, J.; Rios, M.; Palenski, T.; Li, T.; Mato, A. R.
    Blood (2021)

    Fulltext@MSK | Save
  • Dose modification dynamics of ponatinib in patients with chronic- phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials
    Meeting Abstract

    Jabbour, E.; Deininger, M.; Abruzzese, E.; Apperley, J. F.; Cortes, J. E.; Chuah, C.; DeAngelo, D.; DiPersio, J. F.; Hochhaus, A.; Lipton, J. H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Frontline brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone in patients with peripheral T-cell lymphoma with less than 10% CD30 expression (SGN35-032, trial in progress)
    Meeting Abstract

    Jagadeesh, D.; Knowles, S.; Horwitz, S. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy of PBCAR0191, an allogeneic `off-the-shelf' CD19-directed CAR-T for patients with relapsed/refractory (R/R) CD19+ B-ALL
    Meeting Abstract

    Jain, N.; Kantarjian, H.; Solomon, S. R.; He, F.; Sauter, C. S.; Heery, C. R.; List, A. F.; Johnson, M. C.; Lou, Y.; Vainorius, M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Efficient targeting of CD38 in mature T-cell neoplasms with daratumumab and allogeneic NK cells
    Meeting Abstract

    Johnson, W. T.; Isabelle, C.; Vogel, A. N.; Brammer, J. E.; Boles, A. E.; McConnell, K.; Berge, R.; Nisenfeld, L.; Uppal, G.; Gong, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • TP53 mutations identify high-risk peripheral T-cell lymphoma patients treated with CHOP-based chemotherapy
    Meeting Abstract

    Johnson, W. T.; Ganesan, N.; Epstein-Peterson, Z. D.; Maccaro, C.; Galasso, N.; Sauter, C. S.; Neuman, R.; Khan, N.; Moskowitz, A. J.; Dogan, A.; more...
    Blood (2021)

    Fulltext@MSK | Save